Urology Doctors in Logan, UT Accepting Medicare

5 Urology doctors found. Showing 1 - 5

Patrik Luzny, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1350 N 500 E, Logan, UT 84341 Phone: 435-752-1693

David Adams, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1350 N 500 E, Logan, UT 84341 Phone: 435-792-1950    Fax: 435-792-1693

Dr. Michael S Callister, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1350 N 500 E, Logan, UT 84341 Phone: 435-752-0422    Fax: 435-792-1615

Scott Mitchell Heiner, MD Urology Medicare: Medicare Enrolled Practice Location: 1350 N 500 E, Logan, UT 84341 Phone: 435-752-1693    Fax: 435-792-1692

Charles T Swallow, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1350 N 500 E, Logan, UT 84341 Phone: 435-792-1950

News Archive

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Genomic Health, Inc. today reported financial results and business progress for the quarter ended March 31, 2010.

New book from Fraser Institute discusses the government-run health insurance in Canada

As Americans debate the merits of a "public option" for health insurance, a new book published by the Fraser Institute, one of Canada's leading economic think tanks, documents the many significant problems with government-run health care in Canada, providing valuable comparative information for U.S. policy-makers at a crucial moment.

No unique link between first-trimester ACE inhibitor use and birth defects

Women who take angiotensin-converting enzyme (ACE) inhibitors to treat high blood pressure in the first trimester of their pregnancies are at no greater risk of having babies with birth defects than are women who take other types of high blood pressure medication or who take no blood pressure drugs, according to a new study from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality.

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.

Iroko reports positive results from Phase I clinical study of nanotechnology based unique formulation of naproxen

Iroko Pharmaceuticals, LLC today reported the results of the Phase I clinical study of its unique formulation of naproxen, a widely used pain medication, using proprietary, patent protected nanotechnology.

Read more Medical News

› Verified 7 days ago